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Background: Lupus anticoagulant (LA) is an autoantibody that inhibits phospholipid-dependent reactions. Studies on the
incidence and prevalence of LA in the pediatric population are lacking. The objective of our study was to determine the
incidence and potential risk of complications of LA in children presenting with abnormal partial thromboplastin time (PTT). Our
secondary objective was to identify signs, symptoms, and medical history associated with the presence of LA as documented in
the literature. We focused on the correlation between signs of LA in the form of laboratory values consistent with bleeding
abnormalities and the presence of clinical symptoms of bleeding.
Methods: We conducted a record-based retrospective analysis of 112 children and adolescents referred to the Department of
Hematology/Oncology at Children’s Hospital of New Orleans for abnormal coagulation profiles and/or history of
mucocutaneous bleeding. Participants were followed up until PTT values normalized.
Results: In our study population with suspected bleeding disorder, the preliminary incidence of LA was 21%. We found that
resolution of LA correlated with correction of PTT in 90% of patients.
Conclusion: To minimize extensive and expensive blood workup, we recommend that screening for LA be included in the
evaluation of children with prolonged PTT, even if they have a negative history of bleeding problems.
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INTRODUCTION
Lupus anticoagulant (LA) is a misnomer because it is an
acquired immunoglobulin G or immunoglobulin M antibody
that inhibits phospholipid-dependent reactions. LA is usu-
ally associated with certain autoimmune conditions, drugs,
infections, pregnancy loss, bleeding disorders, and malig-
nancies.1 The prevalence of LA is believed to be approxi-
mately 5% in adults, with a predominance among females of
reproductive age.2
The aim of our study was to determine the incidence and
potential risk of complications of LA in children presenting
with abnormal partial thromboplastin time (PTT). Our
secondary objective was to identify signs, symptoms, and
medical history associated with the presence of LA as
documented in the literature.
METHODS
We conducted a retrospective longitudinal analysis of the
medical records of 112 patients who were referred to the
Department of Hematology/Oncology for abnormal coagu-
lation profiles and/or a history of mucocutaneous bleeding.
The abnormal coagulation profiles were incidental findings
during preoperative evaluation. Patients were included in
the trial if they had an abnormally elevated PTT in the
absence of a known bleeding disorder or systemic illness
associated with a bleeding disorder, such as systemic lupus
erythematosus (SLE). The study was conducted using the
records of patients treated at Children’s Hospital of New
Orleans during a period of 3 years. Age, sex, clinical
features, family history of symptomatic bleeding, and
coagulation profiles (mixing study defined as normal if
PTT does not normalize with the addition of normal pooled
plasma, prothrombin time with the reference range defined
as 11-13.5 seconds, PTT with the reference range defined
as 25-35 seconds, dilute Russell viper venom time [dRVVT]
with the reference range defined as 29-42 seconds, and
factor levels when indicated by history) of the patients were
analyzed. Every patient was followed up for PTT and LA
every 12 weeks until all laboratory values returned to
reference range. Appropriate ethical committee clearance
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was obtained from the institutional review board at Child-
ren’s Hospital prior to commencing the study.
RESULTS
Of the 112 children and adolescents who were referred
for abnormal hematologic parameters following preopera-
tive evaluation for a variety of minor surgical procedures, 84
(75%) were found to have prolonged PTT when a
coagulation profile was repeated in our Department of
Hematology/Oncology. These 84 patients underwent mixing
studies, platelet neutralization procedure, dRVVT, factor
levels, and evaluation for antiphospholipid antibody. Twen-
ty-one percent (n¼18) of the prolonged PTT population were
LA positive. The Figure depicts the initial and follow-up PTT
values in the 18 LA-positive patients. Sixty-seven percent
(n¼12) of these LA-positive patients were female, and the
mean age was 6.05 years.
Eighty-nine percent (n¼16) of LA-positive patients were
clinically asymptomatic. The two who were symptomatic
had epistaxis; one required cauterization, and the other
had concomitant thrombocytopenia. Only 2 of the 18 LA-
positive patients had a family history of bleeding disorders;
none of these family members was symptomatic for these
disorders at the time the study was conducted. None of
the LA-positive patients had concomitant factor VIII or
factor IX deficiency. No thrombotic or major hemorrhagic
events were documented in the LA-positive study popula-
tion.
Ten of 18 LA-positive patients later became negative for
LA. PTT normalized in 9 of these 10 patients. The mean time
for normalization of PTT was 3.3 months (range, 3 weeks to
9 months). Eight patients of the 18 initially LA-positive
patients remained positive for LA throughout the follow-up
period. We observed normalization of PTT values in 5 of
these 8 patients. Two of the 8 LA-positive patients had
persistently elevated PTT. One of the 18 initially LA-positive
patients was lost to follow-up.
DISCUSSION
The search for LA began in 1948 when Conley and
Hartmann3 discovered that some of their patients with SLE
had prolonged activated PTT that did not correct after
mixing normal plasma with the patient’s blood. The
unknown compound was named LA, and it was hypothe-
sized to act against negatively charged phospholipids
present on the surface of activated platelets. These
phospholipids are an integral part of the vitamin K–
dependent clotting factor homeostatic cascade. LA belongs
to the group of antiphospholipid antibodies that also
includes the anticardiolipin antibody and the anti-beta-2
glycoprotein I antibody.
For many years, LA was considered insignificant
because patients who tested positive for LA were clinically
asymptomatic despite their prolonged activated PTT.
Attitudes among clinicians regarding the ramifications of
having a positive LA have changed since 1963 when Bowie
et al4 reported thrombotic events in LA-positive patients
with prolonged activated PTT. Today, the presence of LA is
no longer taken to imply that the patient will have a lifelong
history of thrombotic events. In fact, the effect of LA may
only manifest as a transient elevation in PTT without clinical
symptoms as demonstrated in our study. We found LA
positivity to be a transient finding in most of our study
population. Diagnosis of LA is based on the recommen-
dations of the Scientific and Standardization Committee of
the International Society on Thrombosis and Haemosta-
sis.5
No specific tests are available to conclusively diagnose
LA, so the diagnosis is made indirectly. Phospholipid-
dependent tests such as activated PTT and dRVVT are
used as screening tests. The patient’s plasma is mixed
with normal plasma (mixing study), and normalization of
clotting time indicates that confirmatory testing should be
done. Today, phospholipids are added to the patient’s
plasma, and if this addition brings the patient’s clotting
time into the reference range, the patient is said to be
positive for LA.
Once a patient’s blood is established as positive for LA,
repeat confirmatory tests that may include correction/neu-
tralization are done after a 12-week gap. Confounding
factors in the detection of LA are prior treatment with
heparin and freezing of the sample, factors that can have
more of an effect on the results when LA levels are low
and lead to an increase in the number of false-negatives.
Delaying testing for LA is advisable during or immediately
after a thrombotic event or if the patient is taking
anticoagulants.5-9
Patients who are positive for LA are generally asympto-
matic but can present with a thromboembolic event.10
Bleeding is uncommon in LA-positive patients and is usually
associated with an accompanying factor or platelet defi-
ciency.11,12
LA is an acquired immunoglobulin G or immunoglobin M
antibody that inhibits in vitro phospholipid-dependent
reactions. LA assays do not measure antibody titers but
are nonetheless functional tests. Although 1 positive test is
sufficient for LA positivity, 2 or more tests with different
assays are recommended because no single test is 100%
sensitive for LA.13
Continued long-term follow-up and further evaluation are
needed for patients who have persistently prolonged PTT. It
may also be advisable to postpone any planned elective
surgery until the LA has disappeared. In a child with
elevated PTT because of LA, emergency surgery can be
carried out with appropriate precautions such as the
availability of plasma factors. Careful hematologic follow-
up to avoid thrombotic complications is indicated if surgery
is unavoidable. In future work, we hope to address the long-
Figure. Value of partial thromboplastin time (PTT) at initial
presentation and follow-up in 18 patients positive for lupus
anticoagulant.
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term effects of LA in children and adolescents with both
resolved and unresolved prolongation of PTT as they
transition into adulthood.
This condition has principally been studied in the adult
population in whom the prevalence is approximately 5%;
scarce literature is available regarding LA in the pediatric
age group.14 Most physicians agree that LA is a benign
condition often with a transient course lacking significant
clinical issues.15,16 Rare reports exist of thrombosis and
bleeding episodes associated with LA. Patients with such
complications are usually not just positive for LA but also
have coexisting conditions such as factor deficiency, SLE,
and antiphospholipid antibody syndrome.17 Studies report
an association between LA and autoimmune conditions
such as SLE, rheumatoid arthritis, malignancies, urticaria,
vasculitis, and lymphoproliferative disorders.18 Patients with
antiphospholipid syndrome associated with autoimmune
disease are more likely to be older and have a higher
frequency of venous thrombotic events with hematologic
and skin manifestations compared to patients with primary
antiphospholipid syndrome who are more likely to be
younger and have arterial thrombotic events.19 These
differences suggest that the manifestations of LA can be
distinguished based on its association with autoimmune
disease or infection. Drugs such as chlorpromazine;
antibiotics such as amoxicillin; hydralazine; and some viral,
bacterial, and protozoal infections are also associated with
LA.20,21
One limitation of our study is that it is retrospective.
Another limitation is that participants were only followed
until their PTT values normalized. Future work could focus
on the longitudinal effects of LA positivity with or without the
resolution of prolonged PTT, especially in asymptomatic
participants. Long-term effects of LA positivity may be
expected, particularly in females, as anticardiolipin antibod-
ies are associated with an increased risk of miscarriage.22
This risk is relevant in our study population, considering that
LA was more common in females than males. An additional
limitation is the lack of a control group. Future studies could
include a group of participants with prolonged PTT who are
not positive for LA to elucidate how prolonged PTT in the
context of LA positivity differs from prolonged PTT because
of other hematologic anomalies.
CONCLUSION
Based on our study results, we conclude that LA is
common in children and adolescents with abnormal
hematologic parameters and is associated with asympto-
matic presentation notable for prolonged PTT that may
come to medical attention in the context of preoperative
evaluation or other unrelated workup. In our study popula-
tion with suspected bleeding disorders, the preliminary
incidence of LA positivity was 21%. We found that the
resolution of LA correlated with correction of PTT in 90% of
our patients. To minimize extensive and expensive blood
workup, we recommend that screening for LA be included in
the evaluation of children with prolonged PTT, even if they
have a negative history of bleeding problems.
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